MedTrace Logo

Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

NCT03652493 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-06

No results posted yet for this study

Summary

The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination (HR) pathway.

This study may also better characterize the molecular abnormalities of tumors required for the carboplatin response

Conditions

  • Castration-resistant Prostate Cancer
  • Metastasis

Interventions

DRUG

Carboplatin

Tumoral evaluation every 3 cycles

Sponsors & Collaborators

  • French Interregional Group of Clinical Research and Innovation

    collaborator OTHER

  • Ligue Contre le Cancer (French association Against Cancer)

    collaborator UNKNOWN

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2021-04-27
Completion
2021-05-21

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652493 on ClinicalTrials.gov